Is There Value To Be Found In These Stocks? Vringo, Inc.(NASDAQ:VRNG), Terra Tech Corp(OTCMKTS:TRTC), and Galena Biopharma Inc(NASDAQ:GALE)

Posted by Saimoon August 19, 2014 0 Comment 805 views


New York, NY – 08/19/2014 –  HotStockGains provides investors  and traders with valuable trading strategies via text message and email. To join our free text message alerts service just text the word BREAKOUT to 555888 from your cell phone. Just text STOP to unsubscribe if you ever need to.

Vringo, Inc.(NASDAQ:VRNG) gained thirty cents yesterday, a 33.82% increase in value that moved the stock to a closing price of $1.18. Despite the boost in value, the New York-based company remains substantially below the $3 range within which it had previously traded for the majority of the past three months. The stock suffered a large loss of value on Aug. 15th as the stock fell $2.27 to a three month closing price low of $0.88. The loss came in response to the U.S. appeals court’s rejection of I/P Engine, a Vringo subsidiary’s patent claims against Google. The stock gained an additional six cents during after-hours trading.

Will Vringo Remain Above The $1 Mark? Take A Look At Our Free VRNG Analysis.

Terra Tech Corp(OTCMKTS:TRTC) enjoyed a 0.87% boost in value during yesterday’s trading as the stock gained $0.003. Moving to a closing price value of $0.348, the stock nevertheless remains almost $1.07 below its 52 week high of $1.42. The California-based hydroponic equipment company reported its second quarter financial results on Aug. 13th, 2014. The report included a revenue figure of $3,711,801, which represents a 458% increase from the total recorded during the same period in the previous fiscal year.

Can Terra Tech Surpass The $0.40 Mark? Receive A Free TRTC Analysis.

Galena Biopharma Inc(NASDAQ:GALE) fell ten cents to finish the day at a closing price of $2.43. The 3.95% decrease in value placed the stock $5.34 below its 52 week high of $7.77. The Oregon-based biopharmaceutical company announced its second quarter financial results on Aug. 11th. Galena reported an operating loss of $19.9 million, or seventeen cents per basic and diluted share, for the quarter. The company’s cash and cash equivalents figure has decreased by $8.6 million over the past six months.

What Must Galena Biopharma Do To Reverse Its Current Downward Trajectory? Click Here For A Free GALE Analysis.

About HotStockGains

I have a confession to make – I am not always right. Sometimes, unfortunately, I will send alerts that experience losses.

I have alerted companies that rallied 100% or even 6,000% (not even joking) in under a week. Likewise, I have alerted companies that tanked 10, 20, sometimes even as much as 30 or 40%. However overall it is about the net result that delivers profits into your portfolio.

Sign up for my free newsletter to receive market insight, tips, and trading strategies on NYSE, NASDAQ, OTCBB and PINK stocks. If you are not satisfied, simply click unsubscribe.

Disclosure:  HotStockGains is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor (I am not one). Please visit http://hotstockgains.com/disclaimer/ for complete risks and disclosures.


Write Your Comment